Barr Confirms Kos is Seeking Court Order to Block Generic Niaspan

Barr Pharmaceuticals has confirmed that Kos Pharmaceuticals has filed a motion for a temporary restraining order and a preliminary injunction in the United States District Court for the Southern District of New York seeking to prevent Barr from launching generic versions of Kos' Niaspan 500-mg, 750-mg and 1,000-mg extended-release tablets (Niacin extended-release tablets) following final U.S. Food & Drug Administration (FDA) approval.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19339520&full=1)